TW202241448A - 含有依匹斯汀(epinastine)或其鹽及硫系抗氧化劑之經皮投與用醫藥組合物 - Google Patents

含有依匹斯汀(epinastine)或其鹽及硫系抗氧化劑之經皮投與用醫藥組合物 Download PDF

Info

Publication number
TW202241448A
TW202241448A TW110148511A TW110148511A TW202241448A TW 202241448 A TW202241448 A TW 202241448A TW 110148511 A TW110148511 A TW 110148511A TW 110148511 A TW110148511 A TW 110148511A TW 202241448 A TW202241448 A TW 202241448A
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
epinastine
salt
acid
present
Prior art date
Application number
TW110148511A
Other languages
English (en)
Chinese (zh)
Inventor
藤澤豊実
池田紘之
Original Assignee
日商參天製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商參天製藥股份有限公司 filed Critical 日商參天製藥股份有限公司
Publication of TW202241448A publication Critical patent/TW202241448A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW110148511A 2020-12-24 2021-12-23 含有依匹斯汀(epinastine)或其鹽及硫系抗氧化劑之經皮投與用醫藥組合物 TW202241448A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-215228 2020-12-24
JP2020215228 2020-12-24

Publications (1)

Publication Number Publication Date
TW202241448A true TW202241448A (zh) 2022-11-01

Family

ID=82158746

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110148511A TW202241448A (zh) 2020-12-24 2021-12-23 含有依匹斯汀(epinastine)或其鹽及硫系抗氧化劑之經皮投與用醫藥組合物

Country Status (7)

Country Link
US (1) US20240058356A1 (https=)
EP (1) EP4268825A4 (https=)
JP (2) JP7171971B1 (https=)
KR (1) KR20230124625A (https=)
CN (1) CN116744904A (https=)
TW (1) TW202241448A (https=)
WO (1) WO2022138842A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022138842A1 (ja) * 2020-12-24 2022-06-30 参天製薬株式会社 エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物
JP7638310B2 (ja) * 2022-02-28 2025-03-03 久光製薬株式会社 ジャー容器用のブテナフィン含有クリーム剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ242358A (en) * 1991-05-10 1994-03-25 Allergan Inc Use of thiol compounds to inhibit deposits on a contact lens
DE19542281C2 (de) * 1995-11-14 1997-12-04 Boehringer Ingelheim Kg Verwendung von Epinastin für die Behandlung der Migräne
IT1311924B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
KR20050092429A (ko) 2003-01-22 2005-09-21 니찌방 가부시기가이샤 안질환 치료용 경피 흡수형 제제, 그 사용, 및 안질환치료약의 눈의 국소 조직으로의 이행 방법
US20040247686A1 (en) * 2003-04-04 2004-12-09 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
JP5021155B2 (ja) * 2003-08-01 2012-09-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング エピナスチンと１種以上のさらなる抗−ｈ１−ヒスタミン類との組合せを含む皮膚疾患治療用製薬組成物
CN101217948A (zh) * 2005-07-08 2008-07-09 千寿制药株式会社 包含依匹那丁的透皮吸收眼科制剂
EP1985298A1 (en) * 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins
ES2964555T3 (es) * 2009-08-24 2024-04-08 Stealth Biotherapeutics Inc Péptido para uso en la prevención o tratamiento de la degeneración macular
US20140271812A1 (en) * 2013-03-14 2014-09-18 Panacea Pharmaceuticals Treatment for chemotherapy-induced cognitive impairment
EP3302426A4 (en) * 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
WO2018203424A1 (ja) * 2017-05-01 2018-11-08 参天製薬株式会社 点眼剤
JP7458159B2 (ja) * 2018-09-28 2024-03-29 ロート製薬株式会社 眼科組成物
JP2019108320A (ja) * 2018-10-31 2019-07-04 参天製薬株式会社 ソフトコンタクトレンズの変質を抑制する眼科用組成物
JP6736752B2 (ja) * 2019-12-17 2020-08-05 参天製薬株式会社 エピナスチン含有点眼液
WO2022138842A1 (ja) * 2020-12-24 2022-06-30 参天製薬株式会社 エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物

Also Published As

Publication number Publication date
JPWO2022138842A1 (https=) 2022-06-30
EP4268825A1 (en) 2023-11-01
US20240058356A1 (en) 2024-02-22
EP4268825A4 (en) 2024-12-11
JP7171971B1 (ja) 2022-11-15
EP4268825A9 (en) 2025-10-01
JP2023011818A (ja) 2023-01-24
CN116744904A (zh) 2023-09-12
KR20230124625A (ko) 2023-08-25
WO2022138842A1 (ja) 2022-06-30

Similar Documents

Publication Publication Date Title
JP6259042B2 (ja) タペンタドールを含む半固形の水性医薬組成物
JP7171971B1 (ja) エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物
EP3718535B1 (en) Ophthalmic compositions containing a nitric oxide releasing prostamide
JP6934581B2 (ja) エピナスチン又はその塩を含有する水性医薬組成物
JP2025123496A (ja) エピナスチン又はその塩を含有する水性組成物
JPH01121218A (ja) 外用皮膚疾患治療クリーム剤
JP7124248B1 (ja) エピナスチン又はその塩を含有する塗布投与用医薬組成物
JP7191022B2 (ja) アルカフタジン又はその塩を含有する水性医薬組成物
WO2020022368A1 (ja) 液状外用剤
WO2007086582A1 (ja) ２２－オキサ－１α,２５－ジヒドロキシビタミンＤ3を含有する水中油型乳剤性ローション剤およびそれを用いた皮膚疾患の治療方法
CN116669705A (zh) 含有依匹斯汀或其盐的涂布施予用医药组合物
WO2025205960A1 (ja) エピナスチン又はその塩を含有する経皮投与用医薬組成物と抗アレルギー薬との組み合わせ
JP7337791B2 (ja) デスロラタジン又はその塩を含有する医薬組成物
JP2025036319A (ja) クロルフェニラミンマレイン酸塩を含有する医薬組成物
HK40091801A (zh) 含有依匹斯汀或其盐的涂布施予用医药组合物
HK40097614A (en) Pharmaceutical composition for topical administration containing epinastine or salt thereof
JP2024090835A (ja) 組織移行性を向上させるエピナスチン含有水性組成物
WO2024135837A1 (ja) 組織移行性及び防腐効力を向上させるエピナスチン含有水性組成物
JP2022125347A (ja) エピナスチン又はその塩を含有する水性組成物
JP2024090829A (ja) 滅菌容器に収容されるエピナスチン含有水性医薬組成物
JP2020132536A (ja) クロモグリク酸又はその塩を含有する水性医薬組成物